Inhibition of Cholesterol Synthesis Ex Vivo and in Vivo by Fluvastatin, a New Inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase

Overview

Journal Experientia

Specialty Science

Date 1995 Mar 15

PMID 7698284

Authors

A Yamamoto

S Itoh

K Hoshi

K Ichihara

Affiliations

Soon will be listed here.

Abstract

The inhibitory effect of fluvastatin sodium (fluvastatin), a new type of 3-hydroxy-3-methylglutaryl (HMG) coenzyme A inhibitor, on de novo cholesterol synthesis was investigated and compared with that of pravastatin. Fluvastatin at a concentration of 12.5 mg/kg inhibited sterol synthesis ex vivo from [14C]acetate in rat liver and ileum by 97-99% with respect to the control, while the inhibition in kidney was 55%. The inhibition by fluvastatin in the liver and ileum persisted for approximately 9 h after administration. Significant differences between fluvastatin also had an inhibitory effect on cholesterol synthesis in vivo in various tissues of rats given [14C]acetate intraperitoneally. Sterol synthesis in the liver, ileum and kidney was inhibited by over 95% 3 h after administration of 6.25 mg/kg of fluvastatin. Significant differences between fluvastatin and pravastatin were found in the liver and ileum. Fluvastatin was more potent than pravastatin in inhibiting both ex vivo and in vivo sterol synthesis in the ileum (but not in kidney) and liver.

References

Endo A, Tsujita Y, Kuroda M, Tanzawa K . Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977; 77(1):31-6. DOI: 10.1111/j.1432-1033.1977.tb11637.x. View

Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M . Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta. 1990; 1045(2):115-20. DOI: 10.1016/0005-2760(90)90139-o. View

Dietschy J, Wilson J . Regulation of cholesterol metabolism. I. N Engl J Med. 1970; 282(20):1128-38. DOI: 10.1056/NEJM197005142822005. View

Ma P, Gil G, Sudhof T, Bilheimer D, Goldstein J, Brown M . Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986; 83(21):8370-4. PMC: 386930. DOI: 10.1073/pnas.83.21.8370. View

Tanzawa K, Endo A . Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl-coenzyme-A reductase using two specific inhibitors. Eur J Biochem. 1979; 98(1):195-201. DOI: 10.1111/j.1432-1033.1979.tb13177.x. View

Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y . Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem. 1992; 209(1):315-9. DOI: 10.1111/j.1432-1033.1992.tb17291.x. View

Parker R, Clark R, Sit S, Lanier T, Grosso R, Wright J . Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990; 31(7):1271-82. View

Tse F, Labbadia D . Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit. Biopharm Drug Dispos. 1992; 13(4):285-94. DOI: 10.1002/bdd.2510130407. View

Hayashi K, Kurokawa J, Nomura S, Kuga Y, Ohkura Y, Kajiyama G . Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta. 1993; 1167(2):223-5. DOI: 10.1016/0005-2760(93)90166-7. View

10.

Tse F, Smith H, Ballard F, Nicoletti J . Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. Biopharm Drug Dispos. 1990; 11(6):519-31. DOI: 10.1002/bdd.2510110606. View

11.

De Matteis F . Stimulation of liver cholesterol synthesis by actinomycin D. Biochem J. 1968; 109(5):775-85. PMC: 1187028. DOI: 10.1042/bj1090775. View

12.

Heller R, Shrewsbury M . 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver. Its purification, properties, and immunochemical studies. J Biol Chem. 1976; 251(12):3815-22. View

13.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

14.

Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I . CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986; 877(1):50-60. DOI: 10.1016/0005-2760(86)90117-7. View

15.

Hoeg J, Maher M, Zech L, Bailey K, GREGG R, Lackner K . Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol. 1986; 57(11):933-9. DOI: 10.1016/0002-9149(86)90733-2. View

16.

Kovanen P, Bilheimer D, Goldstein J, Jaramillo J, Brown M . Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A. 1981; 78(2):1194-8. PMC: 319974. DOI: 10.1073/pnas.78.2.1194. View